Gilead Sciences Inc. (GILD)
NASDAQ: GILD
· Real-Time Price · USD
106.61
2.40 (2.30%)
At close: Apr 30, 2025, 3:59 PM
105.36
-1.17%
Pre-market: May 01, 2025, 08:54 AM EDT
2.30% (1D)
| Bid | 105.2 |
| Market Cap | 132.9B |
| Revenue (ttm) | 28.75B |
| Net Income (ttm) | 480M |
| EPS (ttm) | 7.74 |
| PE Ratio (ttm) | 13.77 |
| Forward PE | 12.59 |
| Analyst | Buy |
| Ask | 106 |
| Volume | 6,389,423 |
| Avg. Volume (20D) | 9,670,186 |
| Open | 105.33 |
| Previous Close | 104.21 |
| Day's Range | 103.81 - 106.81 |
| 52-Week Range | 62.07 - 119.96 |
| Beta | 0.34 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, V...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Website https://www.gilead.com
Analyst Forecast
According to 23 analyst ratings, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 3.18% from the latest price.
Stock ForecastsEarnings Surprise
Gilead Sciences has released their quartely earnings
on Apr 24, 2025:
6 days ago
-2.81%
Gilead Sciences shares are trading lower after the...
Unlock content with
Pro Subscription
5 days ago
-0.22%
Gilead Sciences shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 EPS guidance.
